Considerations for Drug Development in Myelodysplastic Syndromes

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Myelodysplastic syndromes (MDS) present significant challenges for drug development.
• Historical approaches have faced hurdles due to disease biology, preclinical modeling, and patient population characteristics.

Purpose of the Study:

• To discuss and outline strategies for improving drug development in MDS.
• To address challenges in clinical trial design and endpoints for MDS therapies.

Main Methods:

• Convened a panel of FDA regulators and academic experts in MDS in April 2022.
• Reviewed existing challenges in MDS clinical trial design, response criteria, and endpoints.
• Considered patient-reported outcomes and real-world treatment settings.

Main Results:

• Identified challenges in defining clinical benefit, including response criteria and transfusion thresholds.
• Proposed tailored approaches for lower-risk MDS (focus on anemia, symptoms, quality of life) and higher-risk MDS (focus on survival, durable responses).
• Emphasized the need for trials to reflect disease evolution, patient age, and community-based treatment settings.

Conclusions:

• Future MDS clinical trials require designs that accommodate disease biology and patient characteristics.
• Endpoints should be refined to meaningfully assess clinical benefit and improve patient lives.
• Optimized trial designs can facilitate the development of effective therapies for this high-needs population.